Who are NAs+IFN-α's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): F: Peg-interferon alpha-2a & Ribavirin, C: Peg-interferon alpha-2a & Ribavirin, E: Peg-interferon alpha-2a & Ribavirin, Peg-IFN + WB RBV for 48 weeks, interferon α 2b + ribavirin, Peg-IFN + LD RBV for 24 weeks.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/nas-ifn.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-13 · How we verify

NAs+IFN-α — Competitive Intelligence Brief

NAs+IFN-α (NAs+IFN-α) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Antiviral combination therapy. Area: Virology/Hepatology.

marketed Antiviral combination therapy Hepatitis B virus reverse transcriptase; interferon-alpha receptor signaling Virology/Hepatology Small molecule Live · refreshed every 30 min

Target snapshot

NAs+IFN-α (NAs+IFN-α) — Beijing 302 Hospital. NAs+IFN-α combines nucleos(t)ide analogues with interferon-alpha to suppress hepatitis B virus replication and enhance antiviral immune response.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
NAs+IFN-α TARGET	NAs+IFN-α	Beijing 302 Hospital	marketed	Antiviral combination therapy	Hepatitis B virus reverse transcriptase; interferon-alpha receptor signaling
F: Peg-interferon alpha-2a & Ribavirin	F: Peg-interferon alpha-2a & Ribavirin	Kaohsiung Medical University Chung-Ho Memorial Hospital	marketed	Antiviral combination therapy	Interferon-alpha receptor; Hepatitis C virus RNA-dependent RNA polymerase
C: Peg-interferon alpha-2a & Ribavirin	C: Peg-interferon alpha-2a & Ribavirin	Kaohsiung Medical University Chung-Ho Memorial Hospital	marketed	Antiviral combination therapy	Interferon-alpha receptor; HCV RNA-dependent RNA polymerase
E: Peg-interferon alpha-2a & Ribavirin	E: Peg-interferon alpha-2a & Ribavirin	Kaohsiung Medical University Chung-Ho Memorial Hospital	marketed	Antiviral combination therapy	Interferon-alpha receptor; viral RNA-dependent RNA polymerase
Peg-IFN + WB RBV for 48 weeks	Peg-IFN + WB RBV for 48 weeks	National Taiwan University Hospital	marketed	Antiviral combination therapy	Interferon-alpha receptor; HCV RNA polymerase
interferon α 2b + ribavirin	interferon α 2b + ribavirin	The Immunobiological Technology Institute (Bio-Manguinhos) / Oswaldo Cruz Foundation (Fiocruz)	marketed	Antiviral combination therapy	Interferon-α receptor; viral RNA-dependent RNA polymerase
Peg-IFN + LD RBV for 24 weeks	Peg-IFN + LD RBV for 24 weeks	National Taiwan University Hospital	marketed	Antiviral combination therapy	Interferon alpha receptor; HCV RNA-dependent RNA polymerase

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Antiviral combination therapy class)

Kaohsiung Medical University Chung-Ho Memorial Hospital · 6 drugs in this class
National Taiwan University Hospital · 6 drugs in this class
Casa Sollievo della Sofferenza IRCCS · 1 drug in this class
Hepatitis Resource Network · 1 drug in this class
Hospices Civils de Lyon · 1 drug in this class
MTI Medical Private Limited, Pakistan · 1 drug in this class
Pacific Health Foundation · 1 drug in this class
RedHill Biopharma Limited · 1 drug in this class
Sherief Abd-Elsalam · 1 drug in this class
The Immunobiological Technology Institute (Bio-Manguinhos) / Oswaldo Cruz Foundation (Fiocruz) · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). NAs+IFN-α — Competitive Intelligence Brief. https://druglandscape.com/ci/nas-ifn. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab